A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of
Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced
or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China